ivan_gold_star_

🌀 Deal ✓179 IPO Atea Pharmaceuticals (AVIR) - money on COVID

Long
COVID19:CONFIRMED_US   COVID-19 CONFIRMED US


Stock market. Stocks. IPO of Atea Pharmaceuticals (AVIR) - on October 29, 2020, an IPO of a company specializing in the development of antiviral drugs will take place. The placement is underwritten by J. P. Morgan, Morgan Stanley, Evercore ISI, and William Blair. The deadline for submitting an order with the broker is 20-00 Moscow time on 28.10.2020, the start date of trading is 30.10.2020.

2% of the Fund will be invested in shares of this company. A detailed report on the transaction, or "opportunity card" for all partners of our Fund, will be provided in PDF format. Anyone who wants to get more information, please write in private messages.

5 recent "gold" deals that we published in advance in the network (10% per deal):
At the moment, the equity of all positions +3.5% (start of the Fund 24.10.2020)

1) 23.10.2020 (1) Habib-Geiji result +35%
2) 18.10.2020 (0) Rublev-Chorich result +29%
3) 11.10.2020 (0) Djokovic-Nadal result +75%
4) 30.09.2020 (0) PAOK-Krasnodar result +60%
5) 26.09.2020 (0) Adensanya-Costa result +60%

6 last "silver" deals on the Gold Star Fund (available only to partners of the Fund, 2% deal):
At the moment, the equity of all positions +43.92% (the Fund started working on 13.08.2020)

1) 26.10.2020 (178) IPO Mavenir plc (MVNR) result 0% (the transaction is not closed)
2) 26.10.2020 (177) IPO Root Inc (ROOT) result 0% (deal not closed)
3) 20.10.2020 (176)Dynamo-Juventus result +122%
4) 25.10.2020 (175) Gombos — Sachko result +150%
5) 25.10.2020 (174) Auger Shvartsman, the result is +38%
6) 25.10.2020 (173) Porto Lived Vincere the result is +0%

If you have any questions about cooperation, you can write to the Foundation's founder and Manager Ivan Kuznetsov in private messages.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.